Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "ST-Pharm"

84 News Found

Lupin receives tentative approval from USFDA for DETAF tablets
Drug Approval | February 01, 2023

Lupin receives tentative approval from USFDA for DETAF tablets

DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries


Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets
Drug Approval | January 17, 2023

Lupin receives tentative approval from USFDA for Dolutegravir and Rilpivirine Tablets

Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)


Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma
News | January 06, 2023

Lupin launches novel fixed-dose triple drug combination DIFIZMA DPI to treat Asthma

The estimated national burden of asthma in India is at 17.23 million with an overall prevalence of 2.05% and out of this, approximately 30 lakh patients can be classified under “inadequately controlled”


Biocytogen and Hansoh Pharma announce an antibody license agreement
News | January 05, 2023

Biocytogen and Hansoh Pharma announce an antibody license agreement

Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules


Lupin receives USFDA approval for Brivaracetam Tablets
Drug Approval | December 23, 2022

Lupin receives USFDA approval for Brivaracetam Tablets


Cadila Pharmaceuticals signs IIF with Odisha Government
News | December 08, 2022

Cadila Pharmaceuticals signs IIF with Odisha Government

The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha


CPHI Frankfurt 2022: Global pharma confidence hits record high in CPHI Pharma Index
News | November 26, 2022

CPHI Frankfurt 2022: Global pharma confidence hits record high in CPHI Pharma Index

In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history


USFDA inspects Lupin's Mandideep Unit-1 facility
News | November 25, 2022

USFDA inspects Lupin's Mandideep Unit-1 facility

The inspection of the facility resulted in issuance of a Form-483 with eight observations each for the Drug Product facility and API facility at the site


Lupin receives tentative approval from USFDA for Doxycycline Capsules
Drug Approval | November 09, 2022

Lupin receives tentative approval from USFDA for Doxycycline Capsules

Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US


Lupin receives tentative approval from USFDA for Drospirenone Tablets
Drug Approval | November 07, 2022

Lupin receives tentative approval from USFDA for Drospirenone Tablets

Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US